SCHEMBL5135136

SCHEMBL5135136

CCCCn1c(CN(Cc2ccccc2)Cc2cccc(F)c2F)cnc1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
KDM4E B2RXH2 4/20 0.36
HSD11B1 P28845 2/20 0.35
C5AR1 P21730 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
BCHE P06276 1/20 0.33
PDE4B Q07343 2/20 0.33
NR1H3 Q13133 1/20 0.32
ICMT O60725 2/20 0.32
ADORA2B P29275 1/20 0.32
HSD17B10 Q99714 2/20 0.32
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5074850 0.93 TSHR (0.42) TSHRKDM4EHSD11B1C5AR1ALDH1A1
SCHEMBL5135257 0.92 TSHR (0.40) TSHRKDM4EHSD11B1C5AR1ALDH1A1
SCHEMBL5134519 0.90 TSHR (0.38) TSHRKDM4EC5AR1ALDH1A1HTT
SCHEMBL5072278 0.87 TSHR (0.51) TSHRKDM4EHSD11B1C5AR1ALDH1A1
SCHEMBL5135935 0.87 C5AR1 (0.53) TSHRC5AR1ALDH1A1SMN1; SMN2
SCHEMBL5136720 0.87 TSHR (0.44) TSHRKDM4EHSD11B1C5AR1ALDH1A1
SCHEMBL5137471 0.86 TSHR (0.40) TSHRHSD11B1C5AR1BCHEPDE4B
SCHEMBL5137696 0.86 TSHR (0.41) TSHRKDM4EHSD11B1C5AR1ALDH1A1
SCHEMBL5072389 0.85 TSHR (0.41) TSHRHSD11B1C5AR1ALDH1A1HTT
SCHEMBL5135259 0.85 TSHR (0.41) TSHRKDM4EHSD11B1C5AR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed